Charles Explorer logo
🇨🇿

PARP inhibitors in ovarian cancer FOREWORD

Publikace na 1. lékařská fakulta |
2015

Tento text není v aktuálním jazyce dostupný. Zobrazuje se verze "en".Abstrakt

The fact that most women diagnosed with ovarian cancer initially present in the advanced stages of the disease constitutes one of the greatest barriers to effective treatment. The failure of existing treatments is largely reflected by the fact that ovarian cancer remains the most common cause of gynaecological cancer death, with rates of survival in the UK among the worst in Western Europe (Ovarian Cancer Action, 2014).